^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMP7068

    i
    Other names: IMP7068
    Associations

    News

    Trials
    Company:
    IMPACT Therap
    Drug class:
    WEE1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    10ms
    Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors (ESMO 2023)
    80mg was defined as a potential PR2D in 3/4 schedule, and a second potential RP2D is being explored in 5/2 schedule. RP2D for IMP7068 will be determined soon.
    Clinical • Metastases
    |
    CDK1 (Cyclin-dependent kinase 1)
    |
    IMP7068
    over1year
    WEE1: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=350, Recruiting, Impact Therapeutics, Inc. | N=150 --> 350
    Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MSI-H/dMMR • NTRK fusion
    |
    IMP7068
    3years
    WEE1: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, Impact Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MSI-H/dMMR • NTRK fusion
    |
    IMP7068
    3years
    WEE1: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=150, Not yet recruiting, Impact Therapeutics, Inc.
    Clinical • New P1 trial
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MSI-H/dMMR • NTRK fusion
    |
    IMP7068